Pro Share Advisors LLC Cytokinetics Inc Transaction History

Pro Share Advisors LLC

  • $42.5 Billion
  • Q4 2024

A detailed history of Pro Share Advisors LLC transactions in Cytokinetics Inc stock. As of the latest transaction made, Pro Share Advisors LLC holds 43,299 shares of CYTK stock, worth $1.92 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
43,299
Previous 33,679 28.56%
Holding current value
$1.92 Million
Previous $1.78 Million 14.51%
% of portfolio
0.0%
Previous 0.0%

Shares

31 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Feb 13, 2025
BUY
$46.36 - $58.62 $445,983 - $563,924
9,620 Added 28.56%
43,299 $2.04 Million
Q3 2024

Nov 13, 2024
BUY
$51.22 - $60.16 $364,276 - $427,857
7,112 Added 26.77%
33,679 $1.78 Million
Q2 2024

Aug 13, 2024
SELL
$47.86 - $75.05 $124,436 - $195,130
-2,600 Reduced 8.91%
26,567 $1.44 Million
Q1 2024

May 08, 2024
BUY
$63.75 - $108.06 $338,703 - $574,122
5,313 Added 22.27%
29,167 $2.04 Million
Q4 2023

Feb 14, 2024
BUY
$26.88 - $83.49 $89,832 - $279,023
3,342 Added 16.29%
23,854 $1.99 Million
Q3 2023

Nov 13, 2023
SELL
$29.46 - $36.61 $8,455 - $10,507
-287 Reduced 1.38%
20,512 $604,000
Q2 2023

Aug 10, 2023
BUY
$32.62 - $40.75 $65,011 - $81,214
1,993 Added 10.6%
20,799 $678,000
Q1 2023

May 11, 2023
SELL
$33.36 - $45.71 $78,162 - $107,098
-2,343 Reduced 11.08%
18,806 $661,000
Q4 2022

Feb 02, 2023
BUY
$35.77 - $51.11 $57,768 - $82,542
1,615 Added 8.27%
21,149 $969,000
Q3 2022

Nov 04, 2022
BUY
$38.54 - $54.52 $45,939 - $64,987
1,192 Added 6.5%
19,534 $947,000
Q2 2022

Aug 01, 2022
SELL
$33.93 - $48.92 $279,311 - $402,709
-8,232 Reduced 30.98%
18,342 $721,000
Q1 2022

May 10, 2022
SELL
$29.74 - $46.0 $154,291 - $238,648
-5,188 Reduced 16.33%
26,574 $979,000
Q4 2021

Feb 08, 2022
BUY
$34.35 - $46.38 $54,994 - $74,254
1,601 Added 5.31%
31,762 $1.45 Million
Q3 2021

Nov 12, 2021
SELL
$18.54 - $35.74 $43,513 - $83,881
-2,347 Reduced 7.22%
30,161 $1.08 Million
Q2 2021

Aug 13, 2021
BUY
$19.79 - $26.99 $55,708 - $75,976
2,815 Added 9.48%
32,508 $643,000
Q1 2021

May 14, 2021
BUY
$18.57 - $25.68 $50,417 - $69,721
2,715 Added 10.06%
29,693 $691,000
Q4 2020

Feb 09, 2021
BUY
$15.26 - $28.61 $94,795 - $177,725
6,212 Added 29.91%
26,978 $561,000
Q3 2020

Nov 13, 2020
BUY
$20.58 - $28.96 $54,722 - $77,004
2,659 Added 14.68%
20,766 $450,000
Q2 2020

Aug 03, 2020
BUY
$11.15 - $24.64 $64,190 - $141,852
5,757 Added 46.62%
18,107 $427,000
Q1 2020

May 15, 2020
SELL
$8.75 - $16.3 $83,973 - $156,431
-9,597 Reduced 43.73%
12,350 $146,000
Q4 2019

Feb 12, 2020
SELL
$7.95 - $11.84 $14,015 - $20,873
-1,763 Reduced 7.44%
21,947 $233,000
Q3 2019

Nov 12, 2019
BUY
$10.82 - $14.25 $3,429 - $4,517
317 Added 1.36%
23,710 $270,000
Q2 2019

Aug 13, 2019
SELL
$7.95 - $11.25 $14,063 - $19,901
-1,769 Reduced 7.03%
23,393 $263,000
Q1 2019

May 15, 2019
BUY
$5.95 - $10.19 $1,445 - $2,476
243 Added 0.98%
25,162 $204,000
Q4 2018

Feb 14, 2019
SELL
$5.91 - $9.29 $25,779 - $40,522
-4,362 Reduced 14.9%
24,919 $157,000
Q3 2018

Nov 14, 2018
SELL
$6.4 - $9.85 $7,660 - $11,790
-1,197 Reduced 3.93%
29,281 $288,000
Q2 2018

Aug 13, 2018
SELL
$6.9 - $9.9 $9,080 - $13,028
-1,316 Reduced 4.14%
30,478 $253,000
Q1 2018

May 14, 2018
SELL
$7.2 - $10.05 $35,575 - $49,657
-4,941 Reduced 13.45%
31,794 $229,000
Q4 2017

Feb 14, 2018
BUY
$7.25 - $15.65 $19,357 - $41,785
2,670 Added 7.84%
36,735 $299,000
Q3 2017

Nov 13, 2017
BUY
$12.0 - $15.0 $78,768 - $98,460
6,564 Added 23.87%
34,065 $494,000
Q2 2017

Aug 11, 2017
BUY
N/A
27,501
27,501 $333,000

Others Institutions Holding CYTK

# of Institutions
397
Shares Held
122M
Call Options Held
3.46M
Put Options Held
1.86M
View Full List

About CYTOKINETICS INC

CYTK Quotes by TradingView
  • Ticker CYTK
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 94,144,096
  • Market Cap $4.18B
  • Description
  • Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates i...
More about CYTK
Track This Portfolio

Track Pro Share Advisors LLC Portfolio

Follow Pro Share Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Pro Share Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Pro Share Advisors LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email